OPKO Health, Inc. Proceeds from Lines of Credit
OPKO Health, Inc. (OPK) reported Proceeds from Lines of Credit of $18.66 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-28
- OPKO Health, Inc. proceeds from lines of credit for the quarter ending 2026-06-30 was $10.18M, a 7.69% decline year-over-year.
- OPKO Health, Inc. proceeds from lines of credit for the quarter ending 2026-03-31 was $8.49M, a 51.27% increase year-over-year.
- OPKO Health, Inc. proceeds from lines of credit for the quarter ending 2025-12-31 was $8.53M, a 22.28% decline year-over-year.
- OPKO Health, Inc. proceeds from lines of credit for the quarter ending 2025-09-30 was $7.87M, a 93.98% decline year-over-year.
- OPKO Health, Inc. proceeds from lines of credit for fiscal 2025 was $33.03M, a 92.81% decline from fiscal 2024.
- OPKO Health, Inc. proceeds from lines of credit for fiscal 2024 was $459.43M, a 31.60% decline from fiscal 2023.
- OPKO Health, Inc. proceeds from lines of credit for fiscal 2023 was $671.68M, a 36.61% decline from fiscal 2022.
- OPKO Health, Inc. proceeds from lines of credit for fiscal 2022 was $1.06B, a 37.11% decline from fiscal 2021.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.18M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $18.66M 10-Q/A · filed 2026-08-28 | $27.19M derived: sum of 3 quarters · filed 2026-08-28 | $35.06M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $8.49M 10-Q/A · filed 2026-08-28 | $17.01M derived: sum of 2 quarters · filed 2026-08-28 | $24.88M derived: sum of 3 quarters · filed 2026-08-28 | $35.91M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $8.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.40M derived: sum of 2 quarters · filed 2026-02-26 | $27.42M derived: sum of 3 quarters · filed 2026-08-28 | $33.03M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.87M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $18.89M derived: sum of 2 quarters · filed 2026-08-28 | $24.50M 10-Q · filed 2025-10-29 | $35.48M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $11.03M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $16.64M 10-Q/A · filed 2026-08-28 | $27.61M derived: sum of 3 quarters · filed 2026-08-28 | $158.26M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $5.61M 10-Q/A · filed 2026-08-28 | $16.58M derived: sum of 2 quarters · filed 2026-08-28 | $147.23M derived: sum of 3 quarters · filed 2026-08-28 | $301.34M derived: sum of 4 quarters · filed 2026-08-28 |
| 2024-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $141.62M derived: sum of 2 quarters · filed 2026-02-26 | $295.73M derived: sum of 3 quarters · filed 2026-02-26 | $459.43M 10-K · filed 2026-02-26 |
| 2024-09-30 | $130.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $284.76M derived: sum of 2 quarters · filed 2025-10-29 | $448.46M 10-Q · filed 2025-10-29 | $604.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $154.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $317.81M 10-Q · filed 2025-07-31 | $474.17M derived: sum of 3 quarters · filed 2026-02-26 | $647.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $163.70M 10-Q · filed 2025-05-01 | $320.06M derived: sum of 2 quarters · filed 2026-02-26 | $493.53M derived: sum of 3 quarters · filed 2026-02-26 | $670.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $156.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $329.83M derived: sum of 2 quarters · filed 2026-02-26 | $506.39M derived: sum of 3 quarters · filed 2026-02-26 | $671.68M 10-K · filed 2026-02-26 |
| 2023-09-30 | $173.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $350.03M derived: sum of 2 quarters · filed 2024-11-07 | $515.32M 10-Q · filed 2024-11-07 | $681.29M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $176.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $341.85M 10-Q · filed 2024-08-07 | $507.82M derived: sum of 3 quarters · filed 2025-03-03 | $716.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $165.29M 10-Q · filed 2024-05-07 | $331.26M derived: sum of 2 quarters · filed 2025-03-03 | $540.34M derived: sum of 3 quarters · filed 2025-03-03 | -$424.36M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $165.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $375.05M derived: sum of 2 quarters · filed 2025-03-03 | -$589.65M derived: sum of 3 quarters · filed 2025-03-03 | $1.06B 10-K · filed 2025-03-03 |
| 2022-09-30 | $209.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$755.62M derived: sum of 2 quarters · filed 2023-11-06 | $893.55M 10-Q · filed 2023-11-06 | $1.25B derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-06-30 | -$964.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $684.47M 10-Q · filed 2023-08-03 | $1.04B derived: sum of 3 quarters · filed 2024-03-01 | $1.39B derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-03-31 | $1.65B 10-Q · filed 2023-05-03 | $2.01B derived: sum of 2 quarters · filed 2024-03-01 | $2.35B derived: sum of 3 quarters · filed 2024-03-01 | $2.86B derived: sum of 4 quarters · filed 2024-03-01 |
| 2021-12-31 | $358.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $701.92M derived: sum of 2 quarters · filed 2024-03-01 | $1.21B derived: sum of 3 quarters · filed 2024-03-01 | $1.68B 10-K · filed 2024-03-01 |
| 2021-09-30 | $343.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $854.43M derived: sum of 2 quarters · filed 2022-11-08 | $1.33B 10-Q · filed 2022-11-08 | $1.74B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $510.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $982.80M 10-Q · filed 2022-08-04 | $1.39B derived: sum of 3 quarters · filed 2023-02-27 | $1.70B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $472.21M 10-Q · filed 2022-05-09 | $881.00M derived: sum of 2 quarters · filed 2023-02-27 | $1.19B derived: sum of 3 quarters · filed 2023-02-27 | $1.39B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $408.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $714.22M derived: sum of 2 quarters · filed 2023-02-27 | $921.47M derived: sum of 3 quarters · filed 2023-02-27 | $1.11B 10-K · filed 2023-02-27 |
| 2020-09-30 | $305.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $512.68M derived: sum of 2 quarters · filed 2021-10-28 | $699.08M 10-Q · filed 2021-10-28 | $894.51M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $207.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $393.65M 10-Q · filed 2021-07-29 | $589.08M derived: sum of 3 quarters · filed 2022-03-01 | $648.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $186.40M 10-Q · filed 2021-04-28 | $381.82M derived: sum of 2 quarters · filed 2022-03-01 | $441.48M derived: sum of 3 quarters · filed 2022-03-01 | $445.72M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $195.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $255.09M derived: sum of 2 quarters · filed 2022-03-01 | $259.32M derived: sum of 3 quarters · filed 2022-03-01 | $294.78M 10-K · filed 2022-03-01 |
| 2019-09-30 | $59.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $63.89M derived: sum of 2 quarters · filed 2020-10-29 | $99.35M 10-Q · filed 2020-10-29 | $103.80M derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $39.70M 10-Q · filed 2020-07-31 | $44.14M derived: sum of 3 quarters · filed 2021-02-18 | $47.80M derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-03-31 | $35.46M 10-Q · filed 2020-05-06 | $39.91M derived: sum of 2 quarters · filed 2021-02-18 | $43.56M derived: sum of 3 quarters · filed 2021-02-18 | $55.77M derived: sum of 4 quarters · filed 2021-02-18 |
| 2018-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $8.10M derived: sum of 2 quarters · filed 2021-02-18 | $20.31M derived: sum of 3 quarters · filed 2021-02-18 | $26.92M 10-K · filed 2021-02-18 |
| 2018-09-30 | $3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $15.86M derived: sum of 2 quarters · filed 2019-11-05 | $22.47M 10-Q · filed 2019-11-05 | $39.34M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $12.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $18.82M 10-Q · filed 2019-08-07 | $35.69M derived: sum of 3 quarters · filed 2020-03-02 | $65.71M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $6.61M 10-Q · filed 2019-05-08 | $23.49M derived: sum of 2 quarters · filed 2020-03-02 | $53.51M derived: sum of 3 quarters · filed 2020-03-02 | $91.21M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $46.90M derived: sum of 2 quarters · filed 2020-03-02 | $84.60M derived: sum of 3 quarters · filed 2020-03-02 | $92.42M 10-K · filed 2020-03-02 |
| 2017-09-30 | $30.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $67.72M derived: sum of 2 quarters · filed 2018-11-09 | $75.54M 10-Q · filed 2018-11-09 | $82.14M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $37.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $45.52M 10-Q · filed 2018-08-07 | $52.12M derived: sum of 3 quarters · filed 2019-03-01 | $58.44M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $7.83M 10-Q · filed 2018-05-08 | $14.42M derived: sum of 2 quarters · filed 2019-03-01 | $20.74M derived: sum of 3 quarters · filed 2019-03-01 | $24.98M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $12.91M derived: sum of 2 quarters · filed 2019-03-01 | $17.16M derived: sum of 3 quarters · filed 2019-03-01 | $22.41M 10-K · filed 2019-03-01 |
| 2016-09-30 | $6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $10.57M derived: sum of 2 quarters · filed 2017-11-08 | $15.82M 10-Q · filed 2017-11-08 | $165.80M derived: sum of 4 quarters · filed 2019-01-29 |
| 2016-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $9.50M 10-Q · filed 2017-08-08 | $159.48M derived: sum of 3 quarters · filed 2019-01-29 | $259.80M derived: sum of 4 quarters · filed 2019-01-29 |
| 2016-03-31 | $5.25M 10-Q · filed 2017-05-10 | $155.23M derived: sum of 2 quarters · filed 2019-01-29 | $255.55M derived: sum of 3 quarters · filed 2019-01-29 | $261.43M derived: sum of 4 quarters · filed 2019-01-29 |
| 2015-12-31 | $149.98M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $250.30M derived: sum of 2 quarters · filed 2019-01-29 | $256.18M derived: sum of 3 quarters · filed 2019-01-29 | $261.34M 8-K · filed 2019-01-29 |
| 2015-09-30 | $100.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $106.20M derived: sum of 2 quarters · filed 2016-11-07 | $111.36M 10-Q · filed 2016-11-07 | $118.48M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $5.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $11.04M 10-Q · filed 2016-08-08 | $18.16M derived: sum of 3 quarters · filed 2017-03-01 | $23.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $5.16M 10-Q · filed 2016-05-09 | $12.28M derived: sum of 2 quarters · filed 2017-03-01 | $17.34M derived: sum of 3 quarters · filed 2017-03-01 | $27.35M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $12.19M derived: sum of 2 quarters · filed 2017-03-01 | $22.19M derived: sum of 3 quarters · filed 2017-03-01 | $26.44M 10-K · filed 2017-03-01 |
| 2014-09-30 | $5.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $15.08M derived: sum of 2 quarters · filed 2015-11-09 | $19.33M 10-Q · filed 2015-11-09 | $29.29M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $10.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $14.26M 10-Q · filed 2015-08-05 | $24.22M derived: sum of 3 quarters · filed 2016-02-29 | $33.48M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $4.25M 10-Q · filed 2015-05-11 | $14.21M derived: sum of 2 quarters · filed 2016-02-29 | $23.47M derived: sum of 3 quarters · filed 2016-02-29 | $30.40M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $9.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $19.22M derived: sum of 2 quarters · filed 2016-02-29 | $26.15M derived: sum of 3 quarters · filed 2016-02-29 | $34.58M 10-K · filed 2016-02-29 |
| 2013-09-30 | $9.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $16.18M derived: sum of 2 quarters · filed 2014-11-07 | $24.61M 10-Q · filed 2014-11-07 | $31.73M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $6.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $15.35M 10-Q · filed 2014-08-11 | $22.47M derived: sum of 3 quarters · filed 2015-02-27 | |
| 2013-03-31 | $8.43M 10-Q · filed 2014-05-09 | $15.54M derived: sum of 2 quarters · filed 2015-02-27 | ||
| 2012-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $36.51M 10-K · filed 2015-02-27 | ||
| 2012-09-30 | $29.39M 10-Q · filed 2013-11-12 | |||
| 2011-12-31 | $15.30M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |